Literature DB >> 11848683

Coexpression of GSK-3beta corrects phenotypic aberrations of dorsal root ganglion cells, cultured from adult transgenic mice overexpressing human protein tau.

R Nuydens1, G Van Den Kieboom, C Nolten, C Verhulst, P Van Osta, K Spittaels, C Van den Haute, E De Feyter, H Geerts, F Van Leuven.   

Abstract

Coexpression of constitutively active GSK-3beta[S9A] rescued the axonal pathology induced by overexpression of human tau in transgenic mice (Spittaels et al., (2000) J. Biol. Chem. 275, 41340-41349). We isolated dorsal root ganglion (DRG) neuronal cultures from adult tau4R- and tau4R x GSK-3beta-transgenic mice to define the mechanisms at the cellular and subcellular level. DRG from tau4R-transgenics showed a reduced sprouting capacity while density and stability of microtubules in the axonal processes were significantly increased. Video-enhanced contrast microscopy demonstrated a dramatic inhibition of fast axonal transport. Coexpression of GSK-3beta increased tau phosphorylation and reversed the effects on microtubule stability and saltatory motion. In DRG from GSK-3beta single transgenics, increased tau phosphorylation was evident without any major effects on microtubule stability or axonal transport. These observations support the hypothesis that excess tau competed with motor-proteins for binding to microtubules and/or that a rigid microtubular system inhibits axonal transport.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11848683     DOI: 10.1006/nbdi.2001.0454

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  6 in total

Review 1.  Axonal transport, tau protein, and neurodegeneration in Alzheimer's disease.

Authors:  Dick Terwel; Ilse Dewachter; Fred Van Leuven
Journal:  Neuromolecular Med       Date:  2002       Impact factor: 3.843

Review 2.  Axonal transport defects in Alzheimer's disease.

Authors:  Zi-Xuan Wang; Lan Tan; Jin-Tai Yu
Journal:  Mol Neurobiol       Date:  2014-07-23       Impact factor: 5.590

3.  Yeast as a model system to study tau biology.

Authors:  Ann De Vos; Jayamani Anandhakumar; Jeff Van den Brande; Mathias Verduyckt; Vanessa Franssens; Joris Winderickx; Erwin Swinnen
Journal:  Int J Alzheimers Dis       Date:  2011-04-06

Review 4.  Mechanism-based treatments for Alzheimer's disease.

Authors:  Peter Davies; Jeremy Koppel
Journal:  Dialogues Clin Neurosci       Date:  2009       Impact factor: 5.986

5.  Interactions between Tau and α-synuclein augment neurotoxicity in a Drosophila model of Parkinson's disease.

Authors:  Bidisha Roy; George R Jackson
Journal:  Hum Mol Genet       Date:  2014-01-14       Impact factor: 5.121

6.  Tau pathology is present in vivo and develops in vitro in sensory neurons from human P301S tau transgenic mice: a system for screening drugs against tauopathies.

Authors:  Manuela Mellone; Dimitra Kestoras; Melissa R Andrews; Elisa Dassie; R Anthony Crowther; Gorazd B Stokin; Jon Tinsley; Graeme Horne; Michel Goedert; Aviva M Tolkovsky; Maria Grazia Spillantini
Journal:  J Neurosci       Date:  2013-11-13       Impact factor: 6.167

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.